What side effects are associated with this type of intervention?

Common weight loss treatments, including reduced-calorie diets and increased physical activity, can lead to side effects such as fatigue, irritability, nutritional deficiencies, muscle soreness, joint pain, and risk of injury. Technology-based interventions like JITAI, which provide real-time support, are generally safe but may cause over-reliance on devices, data privacy concerns, and potential anxiety from constant monitoring.

What prior FDA approvals exist?

The FDA has approved several drugs for weight loss, including orlistat, which reduces fat absorption, and sibutramine, which was withdrawn due to cardiovascular risks. More recent approvals include liraglutide and semaglutide, which are GLP-1 receptor agonists that help regulate appetite and caloric intake. These medications, combined with lifestyle modifications, align with the principles of Just-in-Time Adaptive Interventions (JITAI) by providing support to manage dietary and physical activity behaviors.

What other types of research exist?

Promising, novel alternatives to Just-in-Time Adaptive Intervention (JITAI) for weight loss patients in 2024 include: 1) Digital self-help interventions that provide structured guidance and support through internet-based platforms. 2) Smartphone applications that facilitate self-monitoring and offer real-time feedback and motivation. 3) Integrated therapy approaches that combine cognitive-behavioral therapy (CBT) with nutritional counseling and physical activity guidance. These methods leverage technology and evidence-based practices to offer personalized and effective support for weight loss.

← Back to Search

Behavioural Intervention

Behavioral Weight Loss Program for Obesity

N/A

Recruiting

Led By Rebecca J Crochiere, PhD

Research Sponsored by Williams College

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Current BMI = 27-50 kg/m2

Adult (aged 18-65)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to help overweight or obese adults stick to their diet and exercise plans by using smartphone surveys and wearable devices to provide real-time support. The goal is to reduce moments when people are likely to break their routines, improving their chances of successful weight loss.

Who is the study for?

This trial is for adults aged 18-65 in the U.S. with a BMI of 27-50, who own a smartphone with data and can understand English. It's not for those in other weight loss programs, pregnant or planning to be, recently changed weight-related meds, have certain medical/psychiatric risks or eating disorders.

What is being tested?

The study tests how technology like smartphones and Fitbit can track real-time risk factors that lead to lapses during weight loss efforts. The goal is to develop personalized interventions that provide immediate support to prevent these lapses.

What are the potential side effects?

Since this trial involves behavioral changes rather than medication, traditional side effects are not expected. However, participants may experience stress or frustration related to adherence to diet/activity plans and frequent monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My BMI is between 27 and 50.

Select...

I am between 18 and 65 years old.

Select...

I can understand and agree to the study's details.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Physical activity lapse/intention-behavior gap

Secondary study objectives

Dietary lapse

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Behavioral Weight Loss InterventionExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Behavioral weight loss program

2020

N/A

~90

0 / 3Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common weight loss treatments, particularly those similar to Just-in-Time Adaptive Interventions (JITAIs), work by providing personalized, real-time support to address momentary risk factors like cravings or emotional triggers. These interventions use technology such as smartphone apps and sensors to deliver tailored guidance and feedback in the moment, helping individuals stick to their diet and exercise plans. This real-time support is crucial for weight loss patients as it helps prevent lapses in adherence, thereby enhancing the effectiveness of behavioral strategies and increasing the chances of achieving and maintaining weight loss.

Technology-mediated just-in-time adaptive interventions (JITAIs) to reduce harmful substance use: a systematic review.A Randomized Controlled Trial of CBT+: A Clinician-Controlled, Just-In-Time, Adjunctive Intervention for Bulimia-Spectrum Disorders.Feasibility and acceptability of a digital tele-guided intervention targeting components of the addictive appetite model for bulimia nervosa and binge-eating disorder in Korea.